Esketamine nasal spray

DRUG7 trials

Conditions

Cancer PainDepressionDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantDrug InteractionsFood-drug InteractionMajor Depressive DisorderTherapy Resistant Depression

Phase 1

KF2024#1-trial: Esketamine Interaction Study

CompletedNCT06726382

Helsinki University Central HospitalDrug Interactions, Food-drug Interaction

Start: 2024-12-09End: 2025-04-29Updated: 2026-03-05

Phase 2

Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain

WithdrawnNCT04666623

University Hospital, Basel, SwitzerlandCancer Pain

Start: 2020-11-25End: 2023-10-11Updated: 2023-10-19

Phase 3

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

CompletedNCT02782104

Janssen Research & Development, LLCDepressive Disorder, Treatment-Resistant

Start: 2016-06-09End: 2022-12-30Updated: 2025-04-29

ECT vs. Esketamine

WithdrawnNCT04924257

Medical University InnsbruckMajor Depressive Disorder, Treatment Resistant Depression

Start: 2021-07-28End: 2024-04-30Updated: 2022-08-05

Unknown Phase

Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray

NCT04843462

Lukas PezawasMajor Depressive Disorder, Therapy Resistant Depression

Start: 2021-04-29End: 2023-04-14Target: 70Updated: 2022-05-24

Brain Network Dynamics of Depression During Esketamine Treatment

CompletedNCT06012916

University of North Carolina, Chapel HillDepressive Disorder, Major

Start: 2023-07-03End: 2024-08-30Updated: 2024-09-19

(GluEsk) Glutamate and Esketamine

CompletedNCT06432322

University of OxfordDepression

Start: 2024-06-14End: 2025-03-26Updated: 2025-06-08

The International Journal of Neuropsychopharmacology2025-05-0412 citations

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.

2023-08-0912 citations

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA.

2023-03-3124 citations

IMPORTANCE trial: a provisional study-design of a single-center, phase II, double-blinded, placebo-controlled, randomized, 4-week study to compare the efficacy and safety of intranasal esketamine in chronic opioid refractory pain.

2021-01-229 citations

Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study

Psychiatry Research2020-08-0811 citations

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

The International Journal of Neuropsychopharmacology2019-07-09559 citations